ARTICLE SUMMARY:
With transcatheter aortic valve implantation (TAVI) already established as the next blockbuster interventional cardiology market, the focus is now shifting to next-generation TAVI technology. It’s taken ten years, but by significantly reducing atrial regurgitation and enabling clinicians to retrieve and reposition the valve, Direct Flow Medical may be positioned to lead TAVI’s new wave.
Transcatheter aortic valve implantation (TAVI) has gone from a pipe dream that many clinicians did not believe possible to the next major interventional product market in less than 15 years. In doing so, TAVI technology has followed the traditional path of medtech innovation, one especially common in interventional cardiology.
